Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer
– Encorafenib combinations (encorafenib + binimetinib + cetuximab together = encorafenib Triplet; encorafenib + cetuximab together = encorafenib Doublet) showed…